RxDoctor Payments Data

Timothy Bella, MD

Family Medicine · Baton Rouge, LANPI 1205894995

Payments from drug & device makers

$9,289in general payments, 2019–2025

Across 624 payments — averaging $14.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • AstraZeneca$733
  • Lilly USA, LLC$643
  • Amgen$568
  • Merck$506
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$9,277100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,289 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$73,562
Medicare patients
224
Services billed
2,753

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide108$107,959
MounjaroTirzepatide78$91,580
EliquisApixaban54$56,276
JanuviaSitagliptin Phosphate63$54,149
JardianceEmpagliflozin53$50,500
FarxigaDapagliflozin Propanediol51$49,605
RybelsusSemaglutide25$27,822
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$19,095
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog23$18,355
XareltoRivaroxaban27$18,038
Janumet XrSitagliptin Phos/Metformin Hcl17$15,533
TradjentaLinagliptin11$12,974
Tresiba Flextouch U-100Insulin Degludec20$11,827
InvokanaCanagliflozin16$10,296
Atorvastatin Calcium645$6,207

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,098$135,781133 claims
Lilly USA, LLCMounjaro$643$91,58078 claims
MerckJanuvia, Janumet Xr$506$69,68380 claims
Boehringer IngelheimJardiance, Tradjenta$176$63,47464 claims
PfizerEliquis$279$56,27654 claims
AstraZenecaFarxiga$733$49,60551 claims
Johnson & JohnsonXarelto, Invokana$76$28,33343 claims
GSKTrelegy Ellipta$414$19,09528 claims
AbbVieSynthroid$1,900$4,14751 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →